• 1
    Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:123.
  • 2
    Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995;332:5818.
  • 3
    Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, et al. Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006;24:S728.
  • 4
    Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(suppl 2):ii1823.
  • 5
    Larko O. Problem sites: Scalp, palm and sole, and nail. Dermatol Clin 1995;13:7717.
  • 6
    De Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000;25:35762.
  • 7
    Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002;236:126.
  • 8
    Van De Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:15965.
  • 9
    Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action. Dermatology 2004;208:297306.
  • 10
    Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003;290:307380.
  • 11
    Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004;3:61424.
  • 12
    Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. J Am Acad Dermatol 2006;54:S15463.
  • 13
    Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:200413.
  • 14
    Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005;52:42533.
  • 15
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:318.
  • 16
    Stengel FM, Petri V, Campbell GAM, Dorantes GL, López M, Galimberti RL, et al. on behalf of the International IMP25161 study group. Control of moderate-to-severe plaque psoriasis with efalizumab: 24-week, open-label, phase IIIb/IV Latin American study results. Arch Drug Info 2009; in press.
  • 17
    Rich P, Scher RK. Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:20612.
  • 18
    Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001;203:1536.
  • 19
    Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: A randomized, double-blind, placebo-controlled study. Br J Dermatol 2001;145:54653.
  • 20
    Leonardi CL, Sofen H, Krell J, Caro I, Compton P, Sobel JM. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis. J Am Acad Dermatol 2007;56(suppl):AB48.
  • 21
    Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:14526.
  • 22
    Farber EM, Nall L. Nonpustular palmoplantar psoriasis. Cutis 1992;50:40710.
  • 23
    Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf 1992;4:12938.
  • 24
    Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366:136774.
  • 25
    Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:22431.
  • 26
    Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: Report of two patients. Clin Exp Dermatol 2008;33:5202.
  • 27
    Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study. Br J Dermatol 2008;159:4536.
  • 28
    Mössner R, Thaci D, Mohr J, Pätzold S, Bertsch HP, Krüger U, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: Report on five cases. Arch Dermatol Res 2008;300:1015.
  • 29
    Papadavid E, Gazi S, Dalamaga M, Stavrianeas N, Ntelis V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: A case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol 2008;22:3802.
  • 30
    Roux CH, Brocq O, Leccia N, Giacchero D, Breuil V, Albert C, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect? J Rheumatol 2007;34:4347.
  • 31
    Cassetty CT, Alexis AF, Shupack JL, Strober BE. Alefacept in the treatment of psoriatic nail disease: A small case series. J Am Acad Dermatol 2005;52:11012.
  • 32
    Korver JE, Langewouters AM, Van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006;20:12525.
  • 33
    Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE. Alefacept in the treatment of psoriatic nail disease: A proof of concept study. J Drugs Dermatol 2006;5:33940.
  • 34
    Rallis E, Stavropoulou E, Rigopoulos D, Verros C. Rapid response of nail psoriasis to etanercept. J Rheumatol 2008;35:5445.
  • 35
    Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 2008;58:60916.
  • 36
    Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005;53(suppl 1):S1279.
  • 37
    Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis 2006;78:17880.
  • 38
    Carr D, Tusa MG, Carroll CL, Pearce DJ, Camacho F, Kaur M, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat 2008;19:97100.
  • 39
    Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg 2007;11:2025.
  • 40
    Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008;7:9406.
  • 41
    Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008;18:6837.
  • 42
    Bianchi L, Bergamin A, De Felice C, Capriotti E, Chimenti S. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005;52:7367.